Stille AB (SE:STIL)
:STIL
Want to see SE:STIL full AI Analyst Report?
STIL Stock Chart & Stats
kr186.50
-kr9.00(-3.81%)
At close: 4:00 PM EST
kr186.50
-kr9.00(-3.81%)
Day’s Range― - ―
52-Week Rangekr143.00 - kr258.50
Previous CloseN/A
Volume3.08K
Average Volume (3M)6.57K
Market Cap
kr2.13B
Enterprise Valuekr2.03B
Total Cash (Recent Filing)kr138.22M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)23.5
Beta0.07
Next Earnings
Jul 10, 2026EPS Estimate
2.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.31
Shares Outstanding8,985,447
10 Day Avg. Volume9,615
30 Day Avg. Volume6,571
Financial Highlights & Ratios
PEG Ratio-7.86
Price to Book (P/B)2.48
Price to Sales (P/S)3.10
P/FCF Ratio112.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)8.7
Revenue Forecast (FY)kr689.95M
Bulls Say, Bears Say
Bulls Say
Strong MarginsSustained gross (~51%) and EBIT (~15%) margins indicate durable pricing power and operating efficiency in surgical devices. High structural margins support reinvestment in R&D, service infrastructure and cushion profits during volume swings, aiding multi-quarter resilience.
Conservative Balance SheetA debt-free TTM position and historically modest leverage materially lower financial risk. This provides flexibility to fund capex, service the installed base, or endure procurement cycles without refinancing pressure, supporting strategic options over the medium term.
Improving Free Cash FlowMaterial TTM FCF growth and a positive FCF profile enhance the firm’s ability to fund maintenance, aftermarket service expansion and smaller product investments internally. Better cash generation increases optionality for reinvestment and reduces reliance on external capital.
Bears Say
Weak Cash ConversionOperating cash flow coverage (~0.31) and FCF at ~54% of net income show earnings do not reliably convert to cash. Persistent working-capital swings or investment timing can constrain liquidity and limit the durability of reported profits for funding growth or distributions.
Revenue Volatility / Recent DeclineLarge recent revenue decline and an uneven multi-year trajectory undermine predictability. For a capital- and procurement-driven medical-device vendor, lumpy sales reduce visibility for margin leverage and investment planning, increasing execution risk over coming quarters.
Exposure To Hospital Procurement CyclesReliance on hospital capex cycles and procurement timing makes core revenues lumpy and sensitive to budgetary shifts. Structural dependence on large, infrequent purchasing decisions lengthens sales cycles and raises the risk of multi-quarter demand troughs.
STIL FAQ
What was Stille AB’s price range in the past 12 months?
Stille AB lowest stock price was kr143.00 and its highest was kr258.50 in the past 12 months.
What is Stille AB’s market cap?
Stille AB’s market cap is kr2.13B.
When is Stille AB’s upcoming earnings report date?
Stille AB’s upcoming earnings report date is Jul 10, 2026 which is in 70 days.
How were Stille AB’s earnings last quarter?
Stille AB released its earnings results on Apr 24, 2026. The company reported kr2.315 earnings per share for the quarter, beating the consensus estimate of kr1.958 by kr0.357.
Is Stille AB overvalued?
According to Wall Street analysts Stille AB’s price is currently Overvalued.
Does Stille AB pay dividends?
Stille AB pays a Annually dividend of kr1.8 which represents an annual dividend yield of N/A. See more information on Stille AB dividends here
What is Stille AB’s EPS estimate?
Stille AB’s EPS estimate is 2.6.
How many shares outstanding does Stille AB have?
Stille AB has 8,985,447 shares outstanding.
What happened to Stille AB’s price movement after its last earnings report?
Stille AB reported an EPS of kr2.315 in its last earnings report, beating expectations of kr1.958. Following the earnings report the stock price went up 12.391%.
Which hedge fund is a major shareholder of Stille AB?
Currently, no hedge funds are holding shares in SE:STIL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Stille AB
Stille AB develops, manufactures, and sells surgical instruments in Sweden and internationally. It offers artery forceps and ligature clamps; bone cutters and rongeurs; clamps, curettes, raspatories, elevators, forceps, and micro instruments; needle holders, and wire twisting and holding forceps; and osteotomes, chisels, retractors and skin hooks, scissors, and other products, as well as c-arm tables. The company also provides ERCP/abdominal fluoroscopy, neuro/spine, pain management, urology, and vascular surgeries. In addition, it provides instrument repair, maintenance, and inspection services. Further, the company's products are used in various open surgeries. It has a collaboration agreement with GE Healthcare and distribution agreement with Synovis Micro. The company sells through OEM manufacturers of C-frames, distributors, and direct sales. The company was founded in 1841 and is headquartered in Torshälla, Sweden. Stille AB is a subsidiary of Linc AB.